Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials.
Saved in:
| Title: | Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials. |
|---|---|
| Authors: | Ginsberg DA; University of Southern California Keck School of Medicine, Los Angeles, California, USA. ginsberg@ccnt.usc.edu, Oefelein MG, Ellsworth PI |
| Source: | Neurourology and urodynamics [Neurourol Urodyn] 2011 Apr; Vol. 30 (4), pp. 563-7. Date of Electronic Publication: 2011 Jan 25. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Alan R. Liss Country of Publication: United States NLM ID: 8303326 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-6777 (Electronic) Linking ISSN: 07332467 NLM ISO Abbreviation: Neurourol Urodyn Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
